Effects of progesterone on the growth regulation in classical progesterone receptor-negative malignant melanoma cells

Abstract

This study investigated the growth-regulating effects of progesterone (Prog) on nPR-negative malignant melanoma cells and the possible mechanisms. A375 and A875 cells were cultured and treated with Prog of different concentrations. For signal transduction pathway studies, the cells were pretreated with Prog receptor antagonist (RU486, 1×10⁻⁷ mol/L) or MAPK inhibitor (U0126, 5×10⁻⁶ mol/L) for 1 h and then co-incubated with prog (10⁻⁹ mol/L) for another 24 h. Indirect immunofluorescence assay, MTT, flow cytometry and Western blotting were used for assessing the nPR expression, cell growth, cell apoptosis and ERK1/2 Phosphorylation, respectively. Our results showed that lower progesterone concentration promoted the proliferation of both A375 and A875 cells, but this growth-stimulatory effect decreased at progesterone concentration of 1×10⁻⁷ mol/L or higher. The response could be abolished by MAPK inhibitor U0126, but could not be blocked by progesterone antagonist RU486. Flow cytometry exhibited that high concentration (⩾1 × 10⁻⁷ mol/L) progesterone increased the apoptosis of the two cells in a dose-dependent manner. The level of ERK1/2 phosphorylation was increased by a lower progesterone concentration, but reduced by a higher concentration (1×10⁻⁶ mol/L). These results suggest progesterone exerts growth-regulating effects on nPR-negative tumor cells through a non-genomic mechanism.

Keywords

malignant melanoma / progesterone / non-genomic effect

References

[1] ClarkeR.B.. Human breast cell proliferation and its relationship to steroid receptor expression. Climacteric, 2004, 7(2): 129-37

[2] LiX., O’MalleyB.W.. Unfolding the action of progesterone receptors. J Biol Chem, 2003, 278(41): 39261-39264

[3] LeonhardtS.A., BoonyaratanakornkitV., EdwardsD.P.. Progesterone receptor transcription and non-transcription signaling mechanisms. Steroids, 2003, 68(11–13): 761-770

[4] Mulac-JericevicB., ConneelyO.M.. Reproductive tissue selective actions of progesterone receptors. Reproduction, 2004, 128(2): 139-146

[5] WangJ., JiangC., LiX., et al.. The protective mechanism of progesterone on blood-brain barrier in cerebral ischemia in rats. Brain Res Bull, 2009, 79(6): 426-430

[6] GiangrandeP.H., KimbrelE.A., EdwardsD.P., et al.. The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. Mol Cell Biol, 2000, 20(9): 3102-3115

[7] RicherJ.K., JacobsenB.M., ManningN.G., et al.. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem, 2002, 277(7): 5209-5218

[8] GrahamJ.D., ClarkeC.L.. Physiological action of progesterone in target tissues. Endocr Rev, 1997, 18(4): 502-519

[9] ItoK.. Hormone replacement therapy and cancers: the biological roles of estrogen and progestin in tumorigenesis are different between the endometrium and breast. Tohoku J Exp Med, 2007, 212(1): 1-12

[10] CarnevaleR.P., ProiettiC.J., SalatinoM., et al.. Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways. Mol Endocrinol, 2007, 21(6): 1335-1358

[11] PaulssenR.H., MoeB., GrønaasH., et al.. Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids, 2008, 73(1): 116-128

[12] GellersenB., FernandesM.S., BrosensJ.J.. Non-genomic progesterone actions in female reproduction. Hum Reprod Update, 2009, 15(1): 119-138

[13] SmithJ.L., KupchakB.R., GaritaonandiaI., et al.. Heterologous expression of human mPRalpha, mPRbeta and mPRgamma in yeast confirms their ability to function as membrane progesterone receptors. Steroids, 2008, 73(11): 1160-1173

[14] KampaM., PelekanouV., CastanasE.. Membrane-initiated steroid action in breast and prostate cancer. Steroids, 2008, 73(9–10): 953-960

[15] KatzV.L., FarmerR.M., DottersD.. From nevus to neoplasm: myths of melanoma in pregnancy. Obstet Gynecol Surv, 2002, 57(2): 112-119

[16] NeifeldJ.P.. Endocrinology of melanoma. Semin Surg Oncol, 1996, 12(6): 402-406

[17] KandaN., WatanabeS.. 17beta-estradiol, progesterone, and dihydrotestosterone suppress the growth of human melanoma by inhibiting interleukin-8 production. J Invest Dermatol, 2001, 117(2): 274-283

[18] LiJ.W., FangX.F., ChenX., et al.. Selective expression of progesterone receptor in malignant melanoma was inversely correlated with PCNA. J Huazhong Univ Sci Technolog [Med Sci], 2008, 28(2): 216-218

[19] ThomasP.. Characteristics of membrane progestin receptor alpha (mPRalpha) and progesterone membrane receptor component 1 (PGMRC1) and their roles in mediating rapid progestin actions. Front Neuroendocrinol, 2008, 29(2): 292-312

[20] CutiniP., SellésJ., MassheimerV.. Cross-talk between rapid and long term effects of Prog on vascular tissue. J Steroid Biochem Mol Biol, 2009, 115(1–2): 36-43

[21] RevelliA., MassobrioM., TesarikJ.. Nongenomic effects of 1alpha, 25-dihydroxyvitamin D3. Trends Endocrinol Metab, 1998, 9(10): 419-427

[22] MiyauraH., IwataM.. Direct and indirect inhibition of Th1 development by progesterone and glucocorticoids. J Immunol, 2002, 168(3): 1087-1094

[23] MendiberriJ., RauschembergerM.B., SellesJ., et al.. Involvement of phosphoinositide-3-kinase and phospho lipase C transduction systems in the non-genomic action of progesterone in vascular tissue. Int J Biochem Cell Biol, 2006, 38(2): 288-296

[24] RauchC., FlintA.. Non-genomic steroid effects: merging membrane fluidity and receptor-mediated responses. Vet J, 2008, 176(3): 265-266

[25] BlackmoreP.F.. Progesterone metabolites rapidly stimulate calcium influx in human platelets by a src-dependent pathway. Steroids, 2008, 73(7): 738-50

[26] MirmohammadsadeghA., MotaR., GustrauA., et al.. ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis. J Invest Dermatol, 2007, 127(9): 2207-1225